Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory drug approval

FDA Approves ANI Generic Everolimus Tablets

Analysis based on 7 articles · First reported Sep 23, 2026 · Last updated Sep 23, 2026

Sentiment
5
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The approval is a modest positive for ANI Pharmaceuticals, adding a limited-competition generic with roughly $123 million in annual U.S. sales to its portfolio and supporting its multi-product launch target. The impact on Novartis is marginal, as generic entry on a small Afinitor Disperz franchise poses limited revenue risk to the broader company.

pharmaceuticals generics

ANI Pharmaceuticals received final approval from the U.S. United States — Food and Drug Administration for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension in 2mg, 3mg and 5mg strengths. The product is the generic version of Novartis' Afinitor Disperz, which is approved for certain conditions associated with tuberous sclerosis complex. According to IQVIA moving annual total data for July 2026 cited by the company, U.S. annual sales for Everolimus Tablets for Oral Suspension were approximately $123 million. ANI CEO Nikhil Lalwani said the approval reflects continued execution on technically demanding formulations and that the company remains on track to launch at least 15 new generic products in 2026. The approval expands ANI's U.S.-focused generics portfolio and adds to its commercial product lineup. ANIP shares closed at $77.91 on Tuesday, down 1.19%, and traded at $78.99 in pre-market trading following the announcement.

stock
ANI Pharmaceuticals is the central beneficiary of the event, receiving FDA approval for generic Everolimus Tablets for Oral Suspension and expanding its generics portfolio. The approval supports its goal of launching at least 15 new generics in 2026 and adds a product with about $123 million in annual U.S. sales.
Importance 100.0 Sentiment 25.0
govactor
The FDA granted final approval of ANI's ANDA for generic Everolimus Tablets for Oral Suspension, enabling U.S. market entry. The decision is a routine regulatory action with no direct market exposure for the agency itself.
Importance 70.0 Sentiment 0.0
stock
Novartis' Afinitor Disperz faces new generic competition from ANI's approved Everolimus Tablets for Oral Suspension. The affected franchise is small relative to Novartis' overall business, so the financial impact is limited.
Importance 40.0 Sentiment -5.0
per
As ANI's President and CEO, Nikhil Lalwani commented on the approval, highlighting the R&D team's execution and the company's target of launching at least 15 new generics in 2026.
Importance 30.0 Sentiment 10.0
stock
IQVIA provided the market data cited by ANI showing approximately $123 million in annual U.S. sales for Everolimus Tablets for Oral Suspension, framing the commercial opportunity of the approval.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.